[1]. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
Anticancer research [巻]44 [号]2 [頁]781 -786 （2024年） [査読] 有
[DOI] [2]. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
International journal of urology : official journal of the Japanese Urological Association [巻]30 [号]9 [頁]730 -736 （2023年） [査読] 有
[DOI] [3]. Therapeutic effects of KCC2 chloride transporter activation on detrusor overactivity in mice with spinal cord injury.
American journal of physiology. Renal physiology [巻]324 [号]4 [頁]F353 -F361 （2023年） [査読] 有
[DOI] [4]. Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.
International journal of urology : official journal of the Japanese Urological Association [巻]30 [号]1 [頁]57 -61 （2023年） [査読] 有
[DOI] [5]. Effects of Changes in Erectile Function After Holmium Laser Enucleation of the Prostate on Postoperative Outcomes in Patients With Benign Prostatic Hyperplasia.
In vivo (Athens, Greece) [巻]36 [号]6 [頁]2960 -2964 （2022年） [査読] 有
[DOI]